AllianceBernstein
RARE icon

AllianceBernstein’s Ultragenyx Pharmaceutical RARE Stock Holding History

AllianceBernstein’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$645K Buy
28,025
+740
+3% +$16.7K ﹤0.01% 2518
2025
Q4 		$628K Buy
27,285
+577
+2% +$19K ﹤0.01% 2544
2025
Q3 		$803K Sell
26,708
-1,228,495
-98% -$36.8M ﹤0.01% 2450
2025
Q2 		$45.6M Buy
1,255,203
+7,823
+0.6% +$282K 0.01% 623
2025
Q1 		$45.2M Sell
1,247,380
-380,552
-23% -$15.8M 0.02% 613
2024
Q4 		$68.5M Buy
1,627,932
+81,667
+5% +$4.05M 0.02% 511
2024
Q3 		$85.9M Buy
1,546,265
+18,390
+1% +$937K 0.03% 467
2024
Q2 		$62.8M Buy
1,527,875
+45,404
+3% +$1.94M 0.02% 540
2024
Q1 		$69.2M Sell
1,482,471
-96,132
-6% -$4.53M 0.02% 513
2023
Q4 		$75.5M Buy
1,578,603
+46,098
+3% +$1.79M 0.03% 482
2023
Q3 		$54.6M Buy
1,532,505
+18,738
+1% +$742K 0.02% 531
2023
Q2 		$69.8M Buy
1,513,767
+84,353
+6% +$3.91M 0.03% 485
2023
Q1 		$57.3M Sell
1,429,414
-112,263
-7% -$4.82M 0.02% 527
2022
Q4 		$71.4M Buy
1,541,677
+228,144
+17% +$8.97M 0.03% 475
2022
Q3 		$54.4M Buy
1,313,533
+79,409
+6% +$4.08M 0.03% 520
2022
Q2 		$73.6M Sell
1,234,124
-139,305
-10% -$8.57M 0.03% 450
2022
Q1 		$99.7M Buy
1,373,429
+65,273
+5% +$4.54M 0.04% 407
2021
Q4 		$110M Buy
1,308,156
+152,002
+13% +$12.4M 0.04% 420
2021
Q3 		$104M Sell
1,156,154
-25,693
-2% -$2.32M 0.04% 411
2021
Q2 		$113M Buy
1,181,847
+34,414
+3% +$3.59M 0.05% 394
2021
Q1 		$131M Sell
1,147,433
-40,136
-3% -$5.46M 0.06% 330
2020
Q4 		$164M Sell
1,187,569
-193,983
-14% -$23M 0.08% 237
2020
Q3 		$114M Sell
1,381,552
-34,144
-2% -$2.83M 0.06% 283
2020
Q2 		$111M Buy
1,415,696
+2,655
+0.2% +$176K 0.07% 277
2020
Q1 		$62.8M Sell
1,413,041
-134,352
-9% -$6.98M 0.05% 380
2019
Q4 		$66.1M Buy
1,547,393
+211,635
+16% +$8.73M 0.04% 469
2019
Q3 		$57.1M Buy
1,335,758
+170,136
+15% +$9.24M 0.04% 488
2019
Q2 		$74M Buy
1,165,622
+35,390
+3% +$2.25M 0.05% 412
2019
Q1 		$78.4M Buy
1,130,232
+122,009
+12% +$6.97M 0.05% 379
2018
Q4 		$43.8M Buy
1,008,223
+15,866
+2% +$867K 0.03% 513
2018
Q3 		$75.8M Buy
992,357
+50,489
+5% +$4.11M 0.05% 388
2018
Q2 		$72.4M Buy
941,868
+44,556
+5% +$2.88M 0.05% 394
2018
Q1 		$45.8M Buy
897,312
+196,906
+28% +$9.92M 0.03% 511
2017
Q4 		$32.5M Buy
700,406
+56,106
+9% +$2.75M 0.02% 623
2017
Q3 		$34.3M Sell
644,300
-44,906
-7% -$2.66M 0.03% 601
2017
Q2 		$42.8M Buy
689,206
+114,897
+20% +$6.92M 0.03% 522
2017
Q1 		$38.9M Sell
574,309
-93,949
-14% -$7.16M 0.03% 531
2016
Q4 		$47M Buy
668,258
+53,215
+9% +$3.78M 0.04% 470
2016
Q3 		$43.6M Buy
615,043
+236,848
+63% +$15.1M 0.04% 487
2016
Q2 		$18.5M Sell
378,195
-18,344
-5% -$1.19M 0.02% 719
2016
Q1 		$25.1M Buy
396,539
+10,438
+3% +$683K 0.02% 618
2015
Q4 		$43.3M Sell
386,101
-17,616
-4% -$1.76M 0.04% 480
2015
Q3 		$38.9M Buy
403,717
+46,627
+13% +$5.34M 0.03% 492
2015
Q2 		$36.6M Buy
357,090
+52,905
+17% +$4.11M 0.03% 548
2015
Q1 		$18.9M Sell
304,185
-7,888
-3% -$438K 0.02% 746
2014
Q4 		$13.7M Buy
312,073
+3,065
+1% +$140K 0.01% 810
2014
Q3 		$17.5M Buy
309,008
+4,039
+1% +$203K 0.01% 726
2014
Q2 		$13.7M Buy
304,969
+57,872
+23% +$2.38M 0.01% 802
2014
Q1 		$12.1M Buy
+247,097
New +$12.7M 0.01% 808

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

AllianceBernstein's RARE Position: Q1 2026 in Review

AllianceBernstein increased its Ultragenyx Pharmaceutical (RARE) stake by 2.7% in Q1 2026, buying an estimated $16.7K and bringing the position to 28,025 shares worth $645K. The position accounts for ﹤0.01% of the portfolio, ranked #2518.

AllianceBernstein first reported a position in RARE in Q1 2014 and has held it in 49 quarters since. The position peaked at $164M in Q4 2020. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • AllianceBernstein held 28,025 shares of Ultragenyx Pharmaceutical worth $645K as of Q1 2026.
  • AllianceBernstein bought 740 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $16.7K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #2518 holding.
  • AllianceBernstein first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 49 quarters since.
  • AllianceBernstein's Ultragenyx Pharmaceutical position peaked at $164M in Q4 2020.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.